Scancell, a developer of novel immunotherapies for the treatment of cancer, has signed a worldwide licensing and collaboration agreement with ISA Pharmaceuticals, a clinical-stage immunotherapy company.
ISA's AMPLIVANT adjuvant technology will be used for the manufacturing, development and commercialisation of Scancell's first Moditope development candidate, Modi-1.
The partnership has the potential to provide a new treatment option for patients with triple negative breast cancer, ovarian cancer, sarcomas, and other solid tumours.
ISA has granted Scancell an exclusive worldwide license to manufacture, develop and commercialise the AMPLIVANT:Modi-1 conjugate therapy and will contribute know-how and expertise related to AMPLIVANT. Clinical studies will be conducted by Scancell and are expected to commence in H1 2019.
In return, ISA will receive an upfront payment from Scancell and is entitled to milestone and royalty fees following achievement of certain criteria as defined in the agreement.
Cliff Holloway, CEO of Scancell, said: "Our pre-clinical studies have demonstrated Modi-1 induces potent anti-tumour responses and significant improvements in survival. We believe that combining Modi-1 with an enabling adjuvant technology such as AMPLIVANT has the potential to significantly enhance its efficacy in patients and we are looking forward to moving this important and novel therapy into the clinic in the first half of 2019."
At 8:19am: (LON:SCLP) Scancell Holdings PLC share price was +0.5p at 13p